Broader off-label coverage under Part D
Sens. Dianne Feinstein, D-Calif., and Sam Brownback, R-Kan., urge broader access to off-label indications under Medicare Part D in a May 22 letter to the Senate Finance Committee. The senators, who co-chair the Senate Cancer Coalition, urge that Medicare legislation being drafted by the committee include a provision allowing Part D plans to consider the "full range" of evidence in making off-label coverage decisions and bring reimbursement standards for Part D "into line with coverage standards used under Medicare Part B and by commercial insurers." CMS is currently reviewing appropriate compendia for off-label coverage under Part B (1"The Pink Sheet," April 14, 2008, p. 15)
You may also be interested in...
CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.